In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Enanta Pharmaceuticals ( ($ENTA) ) has shared an announcement. On August 20, 2025, Enanta Pharmaceuticals announced it filed a patent infringement ...

Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website.

In the last 3 months, 8 analysts have offered 12-month price targets for Enanta Pharma. The company has an average price target of $31.38 with a high of $48.00 and a low of $15.00.

In the last 3 months, 4 analysts have offered 12-month price targets for Enanta Pharma. The company has an average price target of $54.0 with a high of $65.00 and a low of $48.00.

Oppenheimer analyst Jay Olson lowered the firm’s price target on Enanta (ENTA) to $14 from $16 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 results with ...

Enanta argued that symptom improvement was similar for both antivirals. EDP-235 could be developed and tested in several COVID-related indications, such as long COVID or as a prophylaxis, Luly said.

Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website.

Enanta will not be holding a conference call with today’s quarterly update. The company will provide its next update with the release of the EDP-323 challenge study results, expected in late ...

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its ...